CD8A and neoplasm: Notably, the immunohistochemistry (IHC) results revealed a significant increase in the number of CD8-positive T cells in the tumor tissue after treatment with SRF@Fe(III)-COF + PD-1 (Fig. 7M and N), indicating increased T-cell activation.